ClinicalTrials.gg
Not yet recruitingNCT07659184Updated Jun 24, 2026

IRONCARE: Iron Treatment in Older Patients With Hip Fractures

A Phase 4 interventional study of Ferric Derisomaltose and Oral Iron (Ferrous sulphate) in Hip Fracture, Anemia and Iron, sponsored by University of Aarhus. Not yet recruiting at 5 sites in Denmark. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by University of Aarhus · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
528
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Hip Fractures by University of Aarhus — 2 open to participants now, 2 under way, none of them phase 3. Hip Fractures · University of Aarhus.

Planned enrollment
Largest of 11
528 · median 37
Started
2026
the only one that year
Phase 4
5 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Hip Fractures by University of Aarhus, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 4, and was the 12th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

2 of the 12 studies in Hip Fractures by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hip Fractures by University of Aarhus, or all of them as a file.
02

Study summary

The aim of this study is to investigate the effects of intravenous (IV) iron therapy compared to alternate-day oral iron treatment and no supplementation in older patients with hip fractures. This study will examine the impact of iron treatment on fatigue, functional decline, fear of falling, cognitive impairment, and quality of life, as well as its effects on iron stores and hemoglobin levels, with the overall goal of improving postoperative rehabilitation.

The trial will be conducted on five different hospitals in the Central Region of Denmark (Region Midtjylland).

03

Conditions studied

  • Hip Fracture
  • Anemia
  • Iron
  • Placebo - Control

Keywords

  • Hip fracture
  • Anemia
  • iron
  • Intravenous iron
  • mobility
  • fatigue
  • hemoglobin
  • RCT
  • Placebo
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hip fracture (ICD-10 codes: DS720, DS721 and DS722)
  • Low energy trauma
  • Age ≥ 75 years
  • ≤7.0 mmol/L (11 g/dL) during hospital admission

Exclusion criteria

Exclusion Criteria:

  • Pathological fracture
  • Periprosthetic fracture
  • Inability to understand or speak Danish
  • Dysphagia and thus inability to swallow study medication
  • Signs of iron overload, hemochromatosis, or hemosiderosis
  • Liver disease (cirrhosis or hepatitis) and transaminase levels >3 times
  • Known allergy to iron formulations
  • Severe asthma
  • Severe hypophosphatemia: \<0.35 mmol/L
  • Patients already receiving iron supplementation that cannot be paused for the study period
  • Cognitive impairment that results in either memantine-treatment or a Short Portable Mental Status Questionnaire (SPMSQ) score > 4
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
528 participants (estimated)

Study arms

  • Active comparator
    IV Iron

    Intravenous iron once and placebo tablets on alternate days for 90 days

    Drug: Ferric Derisomaltose · Drug: Placebo Tablets

  • Active comparator
    Oral Iron

    Intravenous sodium chloride once and ferro sulfate tablets on alternate days for 90 days

    Drug: Oral Iron (Ferrous sulphate) · Drug: Placebo IV

  • Placebo comparator
    Placebo

    Intravenous sodium chloride once and placebo tablets on alternate days for 90 days

    Drug: Placebo IV · Drug: Placebo Tablets

Interventions

  • DrugIron isomaltoside 1000Studies of Iron isomaltoside 1000Iron isomaltoside 1000 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous Ferric Derisomaltose shortly after surgery and placebo tablets on alternate days for 90 days

  • DrugIronStudies of IronIron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral iron sulfate on alternate days for 90 days and IV placebo once shortly after surgery

  • DrugPlacebo IV

    100 ml Sodium Chloride (NaCl)

  • DrugPlacebo Tablets

    Placebo tablets on alternate days for 90 days

06

What researchers measure

Primary outcomes

  1. Fatigue

    Measured by Multidimensional Fatigue Inventory tool (MFI-20). MFI-20 is a questionnaire of 20 questions answered on a 5-point scale from "yes, that is true" (1 point) to "no, that is not true" (5 points). A higher score indicates greater severity of fatigue.

    Time frame: Baseline and days 30 and 90 after discharge

  2. Hemoglobin increment

    Defined as a change of level of a minimum of 1.24 mmol/L (2 g/dL). The level of hemoglobin will be measured with a venous blood sample

    Time frame: Baseline and days 30 and 90 after discharge

  3. Safety profile

    Measured as the prevalence and severity of adverse events associated with iron treatment

    Time frame: Days 15, 30, 45 and 90 after discharge

Secondary outcomes

  1. Physical function - NMS

    New Mobility score (NMS) is used to assess the participant's mobility. The participant will be asked three questions ranging from "no difficult and no walking aid" (3 points) to "not able to at all" (0 points). The score ranges from 0 - 9 points. A higher score indicates a higher level of independent mobility.

    Time frame: Baseline and days 30 and 90 after discharge

  2. Physical function - handgrip strength

    Handgrip strength is measured by using a dynamometer that measures the pressure made from a hand grip on the dynamometer in kilograms. A higher score indicates higher handgrip strength.

    Time frame: Baseline and days 30 and 90 after discharge.

  3. Physical function - 30 second sit-to-stand-test

    30 second sit-to-stand-test is used as a parameter for strength, muscle power and dynamic balance. The test is performed by placing a chair with the back against a wall. The participant must be seated on the chair with their arms crossed and are then encouraged to fully stand and sit as many times as possible in 30 seconds. If the arms are used to stand, the score will be 0. A low score indicates low physical ability, and a higher score indicates high physical ability.

    Time frame: Baseline and days 30 and 90 after discharge.

  4. Fear of Falling

    Measured by Short Fall Efficiency Scale-International which is a 7 questions questionnaire assessing the fear of falling from 7 points (low concern of falling) to 28 points (high concern of falling).

    Time frame: Days 30 and 90 after discharge

  5. Cognitive impairment

    Measured by Brief Assessment of Impaired Cognition (BASIC). The tool consists of three questions to the patient (0-6 points), word finding (0-5 points), categorized recalling of photos (0-8 points) and lastly three questions to a next of kin (0-6 points). A low score indicates impaired cognition. In cases where no next of kins is available the conversion table is used of an estimated score according to the guidance from the Danish Dementia Research Centre.

    Time frame: Baseline and days 30 and 90 after discharge

  6. Quality of life

    European Quality of Life - 5 Dimensions (EQ-5D-5L) which is a standardized questionnaire used to evaluate health-related quality of life. There are 5 questions ranging from level 1 - 5 Level 1 indicates: no problems Level 2 indicates: slight problems Level 3 indicates: moderate problems Level 4 indicates: severe problems Level 5 indicates: extreme problems And lastly a visual analogue scale from 0 - 100 where 100 means the best health imaginable and 0 means the worst health imaginable.

    Time frame: Baseline and 90 days after discharge

  7. Biochemical iron status - transferrin

    p-transferrin (μmol/L) measured by a venous blood sample.

    Time frame: Baseline and on days 30 and 90 after discharge

  8. Biochemical iron status - ferritin

    p-ferritin (μg/L) measured by a venous blood sample

    Time frame: Baseline and on days 30 and 90 after discharge

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: Yes — Upon relevant request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.

Of 33 non-industry phase 4 interventional studies under Hip Fractures, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 23 months is close to that.

Counting every sponsor, half of 33 studies reached it within 25 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 22, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07659184
Collaborators
Region MidtJylland Denmark, Viborg Regional Hospital, Gødstrup Hospital, Aarhus University Hospital, Randers Regional Hospital, Regionshospitalet Horsens
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jun 24, 2026

Study contacts

Ole Vincent Ancker, MD
Contact
ole.ancker@rm.dk
+4551322385
Merete Gregersen, ph.d.
Contact
meregreg@rm.dk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iron isomaltoside 1000 · Iron

Start the discussion